Tanshinone IIA inhibits glucose metabolism leading to apoptosis in cervical cancer

ZHIGANG LIU1*, WENHE ZHU2*, XIANGYU KONG1, XI CHEN1, XINYI SUN1, WEI ZHANG2 and RUOWEN ZHANG1

1Faculty of Medicine, Beihua University; 2Department of Biochemistry, Jilin Medical University, Jilin, Jilin 132013, P.R. China

Received February 13, 2019; Accepted July 16, 2019

DOI: 10.3892/or.2019.7294

Abstract. Cancer requires aerobic glycolysis to supply the energy required for proliferation. Existing evidence has revealed that blocking glycolysis results in apoptosis of cancer cells. Tanshinone IIA (Tan IIA) is a diterpenoid naphthoquinone found in traditional Chinese medicine, Danshen (Salvia sp.). Tan IIA exhibits potential anticancer activity. However, its effect on cell viability of human cervical cancer cells and its mechanism are unknown. The aim of the present study was to determine the effect of Tan IIA on proliferation and glucose metabolism in cervical cancer cells. Cell viability was measured by MTT assay, apoptosis was determined using flow cytometry and glucose uptake, lactate production, and adenosine triphosphate content were measured to assess glucose metabolism. The expression of apoptosis-associated proteins was detected by western blotting and the antitumor activity of Tan IIA in vivo was evaluated in cervical carcinoma-bearing mice. The results revealed Tan IIA treatment resulted in a considerable reduction in the viability of SiHa cells. Tan IIA decreased the expression of HPV oncogenes E6 and E7, induced apoptosis and also decreased glycolysis by suppressing the activity of the intracellular AKT/mTOR and HIF-1α. In vivo, treatment with Tan IIA resulted in a 72.7% reduction in tumor volume. The present study highlights the potential therapeutic value of Tan IIA, which functions by inducing apoptosis and may be associated with inhibition of glycolysis.

Introduction

Cervical cancer is one of the most common malignant carcinomas amongst women worldwide. There are an estimated 530,000 new cases of cervical cancer annually with 270,000 cancer-related deaths (1,2). Infection with high-risk human papillomaviruses (HPVs), such as HPV16 and HPV18, is the primary cause of cervical cancer, amongst multiple factors (3). Understanding that HPV infection is the primary inducer of development of cervical cancer has improved prevention of cervical cancer (4). At present, the strategies for treatment of cervical cancer include surgery, radiation and chemotherapy. However, the severe systemic toxicity caused by radiation and chemotherapy affect prognosis (4-7). Therefore, developing a safe therapeutic strategy for cervical cancer treatment is desirable.

Isolating components of traditional medicines with anti-neoplastic activities has been demonstrated as a promising alternative strategy for treating patients with cancer (8,9). Tanshinone II A (Tan IIA) is the primary lipophilic component isolated from the traditional Chinese medicine Salvia miltiorrhiza. Numerous animal and clinical studies have demonstrated that Tan IIA is an effective reagent commonly used for the prevention and treatment of cardiovascular diseases, including atherosclerosis via its antioxidant and anti-inflammatory activities (10-12). Tan IIA has recently attracted considerable attention in cancer therapy due to its potential antitumor activities. The antitumor effect of Tan IIA has been verified in various cancer cell lines, including glioma, osteosarcoma, leukemia, prostate, breast, colon, lung, liver, stomach, pancreas, bile duct, kidney, ovarian, cervical and nasopharyngeal cells (13-16). Studies have demonstrated that Tan IIA may suppress the growth and induce apoptosis in certain types of cancer cells through multiple mechanisms, including cell cycle arrest and caspase-dependent apoptosis (17,18). However, the antitumor mechanisms of Tan IIA remain unknown.
Over the last decade, advances in understanding of the metabolism in cancer cells has revealed that cancer cells predominantly rely on aerobic glycolysis to maintain cell proliferation (19,20). Inhibition of aerobic glycolysis in tumors has been identified as an effective strategy to aid in overcoming obstacles in cancer treatment, and the effectiveness of this approach has been validated in pre-clinical studies (21). Inhibiting glycolysis in a tumor may be an effective treatment strategy for potential future treatments (22-24).

Several studies have reported that Tan IIA inhibits proliferation in cervical cancer cells by inducing apoptosis in these cells (25,26). However, previous research has only focused on the use of Tan IIA to induce tumor cell apoptosis. The role of Tan IIA on inhibition of glycolysis in cervical cancer has not been studied. The aim of the present study was to examine the effect of Tan IIA on cell growth in cervical cancer and determine the underlying mechanism, by assessing change in metabolic phenotype and apoptosis. The present study provides insight into the molecular mechanism through which Tan IIA induces apoptosis in cervical cancer and highlights the potential use of Tan IIA as a novel therapeutic agent for treating patients with cervical cancer.

Materials and methods

Materials. Human cervical cancer cell lines SiHa (HPV 16-positive cells), HeLa (HPV 18-positive cells) and C33a (HPV negative) were provided by the Chinese Academy of Sciences (Shanghai, China). Dulbecco's Modified Eagle's Medium (DMEM) and fetal bovine serum (FBS) were purchased from Thermo Fisher Scientific, Inc. Dimethyl sulfoxide (DMSO, analytical grade) was obtained from Beijing Chemical Reagent Factory. Tan IIA was obtained from PhytoMyco, Inc. The mouse anti-human Bcl-2 antibody (cat. no. sc-23960), mouse anti-human Bax antibody (cat. no. sc-20067), rabbit anti-human cleaved caspase-3 antibody (cat. no. sc-7148), mouse anti-human cleaved caspase-9 antibody (cat. no. sc-17784), mouse anti-human cytochrome c antibody (cyto c; cat. no. sc-13561) were obtained from Santa Cruz Biotechnology, Inc. Rabbit anti-human p-AKT antibody (ID product code ab18206), rabbit anti-human AKT antibody (ID product code ab8805), rabbit anti-human p-mTOR antibody (ID product code ab84400), rabbit anti-human mTOR antibody (ID product code ab2732) were obtained from Abcam, Inc. Rabbit anti-human GLUT1 antibody (cat. no. PA5-16793), rabbit anti-human PKM2 antibody (cat. no. PA5-23034), rabbit anti-human HK2 antibodies (cat. no. PA5-29326) were purchased from Invitrogen; Thermo Fisher Scientific, Inc.

Cell culture. SiHa, HeLa and C33a cells were maintained in DMEM supplemented with 10% FBS, 100 units/ml of penicillin and 100 units/ml of streptomycin at 37°C in a humidified atmosphere of 5% carbon dioxide (CO₂) and 95% air. Cells were sub-cultured every three days with 0.25% trypsin.

Cytotoxicity assay. The cytotoxicity of Tan IIA on tumor cells was detected by MTT assay (27). SiHa, HeLa and C33a cells were seeded into a 96-well assay plate with a concentration 1.0x10^5 cells/ml (200 µl/well). After 24 h of incubation, the cells were treated with Tan IIA with doses of 0-8 mg/l in the growth medium. Each concentration was assessed five times. The cells were cultured for another 24, 48 and 72 h. Subsequently, 20 µl of MTT (5 mg/ml) was added to each well and incubated for another 4 h. Then, supernatant was discarded and 150 µl DMSO was loaded to each well. The optical density (OD) was measured at 490 nm using a Bio-assay reader (Bio-Rad 550; Bio-Rad Laboratories, Inc.).

Quantitative reverse transcription PCR (qRT-PCR). The total RNA form Tan IIA-treated and untreated SiHa cells were extracted to detect the expression of HPV16-E6/E7 gene. Total cellular RNA was isolated using TRIzol reagent (Invitrogen; Thermo Fisher Scientific, Inc.) as per the manufacturer’s protocol. A high-capacity cDNA reverse-transcription kit was used to prepare cDNA (Thermo Fisher Scientific, Inc). qRT-PCR was carried out using gene-specific oligonucleotide primers (Table I), an iScript One-Step RT-PCR kit with SYBR-Green and an ABI 7500 Fast real-time PCR system. The PCR conditions were set as 95°C for 5 min, followed by 40 cycles at 95°C for 30 sec, 60°C for 45 sec and 72°C for 30 min. All values were normalized to β-actin and then standardized to the control condition. Error bars represent the standard error of the mean (SEM), and the statistical significance was assessed using the Student’s t-test. After completion of the RT-PCR, Cq values were obtained using the ABI 7500 fast v2.0.1 software. The ΔΔCq method was used to represent mRNA fold change (28).

Flow cytometric evaluation of apoptosis. After Tan IIA treatment, SiHa cells were harvested by centrifugation at 1,000 x g for 3 min and washed with PBS twice. Then, the cells were re-suspended in 100 µl DMEM medium. Then 100 µl Muse Annexin V and Dead Cell reagents were added and incubated at room temperature for 20 min. The percentage of apoptosis was detected and analyzed using a Muse Cell Analyzer (EMD Millipore).

Caspase-3/7 activation detected. The caspase-3/7 activation change was detected by Muse Cell Analyzer following the manufacturer’s instructions. After Tan IIA treatment, SiHa cells were harvested by centrifugation at 850 x g and the cell pellet was resuspended in 50 µl PBS. Muse Caspase-3/7 reagent working solution (5 µl) was added to the cell suspension, and it was mixed thoroughly and incubated at 37°C for 30 min. After incubation, 150 µl of Muse™ Caspase 7-AAD working solution was loaded to each sample, and incubated at room temperature for 5 min. Then, the caspase-3/7 activation was detected by Muse Cell Analyzer.

Measurements of glucose uptake levels and lactate production. The SiHa cells were seeded in 6-well plates at a density of...
1x10^4 cells/well. After treatment with Tan IIA for 48 h, the cell culture media was collected to detect the glucose uptake and lactate production. For assessment of lactate production, the collected culture media was diluted 1:50 by using lactate assay buffer. The amount of lactate present in the media was then estimated using the Lactate Assay kit (Sigma-Aldrich; Merck KGaA) according to the manufacturer’s instructions. The content of glucose in the collected culture media was detected immediately using a Glucose Assay kit according to the manufacturer’s instructions. Glucose uptake and lactate production were all normalized by cell number (29).

**Determination of ATP content.** SiHa cells were seeded in 6-well plates (1x10^5 cells/ml) and then incubated with Tan IIA for 48 h. Then, the cells were harvested and lysed on ice with somatic cell ATP releasing reagent. The ATP content was detected by ATP assay kits (Genmed Sciences, Inc.) according to the manufacturer’s instructions. ATP content was normalized by cell number (29).

**Western blot analysis.** After Tan IIA treatment, 5x10^5 SiHa cells were harvested and lysed in RIPA buffer (Sigma-Aldrich; Merck KGaA) to extract the total protein. The extract total protein content was determined by Bio-Rad BCA protein assay kit and 50 µg protein /lane was loaded on 12% SDS-PAGE. After SDS-PAGE, the separated proteins were transferred to nitrocellulose membranes. Non-specific binding was blocked with 5% non-fat dry milk in TBS/0.1% Tween for 120 min. After blocking, the blots were incubated with primary antibody: Bcl-2 antibody (dilution 1:2,000), Bax (dilution 1:2,000), cleaved caspase-3 (dilution 1:2,000), cleaved caspase-9 (dilution 1:2,000), cyto c antibody (dilution 1:2,000), p-AKT (dilution 1:1,000), AKT (dilution 1:1,000), p-mTOR (dilution 1:1,000), mTOR (dilution 1:1,000), GLUT1 (dilution 1:1,000), PKM2 (dilution 1:1,000), HK2 (dilution 1:1,000) at 4˚C overnight. Then, the appropriate secondary antibody (cat. nos. sc-2357 and sc-516132; Santa Cruz Biotechnology) at a 1:5,000 dilution was added and incubation followed for 1 h at room temperature. Immunoreactive protein bands were detected by chemiluminescence using enhanced chemiluminescence reagents (ECL) was obtained from Santa Cruz Biotechnology, Inc. Blots were also stained with anti-β-actin antibody (cat. no. 60008-1-lg; Proteintech Group) as an internal control for the amounts of target proteins. The films were then subjected to densitometry analysis using a Gel Doc 2000 system (Bio-Rad Laboratories, Inc.).

**Histopathological and morphological examination.** The tumor tissues were excised and fixed at 25°C for one week in 4% formalin, embedded in paraffin, and cut into 4-mm sections for histological study. Hematoxylin and eosin (H&E) purchased form Sigma-Aldrich (Merck KGaA) was used to stain the tumor for histological analysis. Histopathological analysis of the tumor tissue sections was performed using a light microscope at an x200, magnification.

**Statistical analysis.** Results are presented as the mean ± SEM which are derived from three or more independent experiments. All data were analyzed by one-way ANOVA using SPSS version 13 software (SPSS, Inc.). Tukey’s post hoc test was used to determine the significance for all pairwise comparisons of interest. A value of P<0.05 was considered to indicate a statistically significant difference.

### Results

**Tan IIA inhibits the cell viability against human cervical cancer cells.** An MTT assay was performed to determine the cytotoxicity of Tan IIA in SiHa, HeLa, and C33a cells after...
48 h of treatment. The results revealed that Tan IIA significantly inhibited cell viability in SiHa, HeLa, and C33a cells in a dose-dependent manner (Fig. 1A). Tan IIA had a greater inhibitory effect on cell viability in SiHa and HeLa cells compared with the HPV-negative C33a cells. Thus, SiHa cells were used for all subsequent experiments.

**Tan IIA suppresses HPV16-E6/E7 gene expression.** The effect of Tan IIA expression on mRNA expression of HPV16-E6/E7 in SiHa cells was determined using reverse transcription-quantitative (RT-q)PCR (Fig. 1B). Treatment with Tan IIA (1.5 mg/l) resulted in a significant reduction in the mRNA expression of HPV E6 and HPV E7. Western blot analysis also confirmed the results of the RT-qPCR (Fig. 1C).

**Tan IIA induces SiHa cell apoptosis.** Hoechst 333258 was used to stain apoptotic nuclei. Hoechst 333258 staining revealed that the nuclei appeared as uniform blue with organized chromatin structure in the control group (Fig. 2A). Following treatment with Tan IIA at a range of concentrations (0.5, 1 and 2 mg/l) for 48 h, the SiHa cells were decreased in number and presented with smaller nuclei, strong fluorescent spots, pyknotic nuclei and extensive blebbing. Condensed chromatin and apoptotic bodies were observed under a fluorescence microscope in the treated cells suggesting that the Tan IIA treatment had induced apoptosis in the SiHa cells. Similar results were obtained from staining with Muse Annexin V and Dead Cell reagents. As revealed in Fig. 2B and C the percentage of early apoptotic cells was increased as the dose of Tan IIA increased compared with the untreated group (P<0.01).

**Detection of caspase-3/7 activation.** Muse caspase-3/7 assay kits were used to detect caspase-3/7 activation following treatment with Tan IIA in the SiHa cells. Stained cells were quantified using a Muse cell analyzer. The percentage of cells in early apoptosis was 4.9, 10.55, and 22.55% when treated with 0.5, 1 and 2 mg/l Tan IIA, respectively (Fig. 2D and E).

**Inhibitory effect of Tan IIA on glucose uptake, lactate generation, and adenosine triphosphate (ATP) production.** Tumor cells use glucose as a substrate for ATP synthesis and production. Glucose uptake in SiHa cells following treatment with Tan IIA for 48 h was measured. The results revealed that glucose uptake in Tan IIA-treated SiHa cells was decreased (Fig. 3A). The primary product of aerobic glycolysis is lactic acid and ATP. Thus, the ATP and lactic acid content were measured using reagent kits to investigate whether glycolysis inhibition was associated with Tan IIA-mediated SiHa cell apoptosis. The results revealed that the levels of intracellular ATP and extracellular lactic acid were decreased in SiHa cells treated with Tan IIA (0.5, 1 and 2 mg/l) compared with the control group (Fig. 3B and C).
Tan IIA induces SiHa cell apoptosis through the mitochondrial apoptosis pathway. Western blotting was used to assess the expression of apoptosis-associated proteins in Tan IIA-treated SiHa cells to determine which apoptosis pathway underlied Tan IIA activity in apoptosis of cervical cancer cells. As revealed in Fig. 4, after treatment with increasing doses

Figure 2. Effect of Tan IIA on apoptosis and caspase-3/7 activation in SiHa cells. (A) Following treatment with increasing concentrations of Tan IIA for 48 h, SiHa cells were stained with Hoechst 33258, and the morphology was observed using a fluorescence microscope. Magnification, x200. (B) SiHa cells were treated with different concentrations of Tan IIA, and apoptosis was assessed using a Muse Cell Analyzer. (C) Quantification of apoptotic cells. (D) Analysis of caspase-3/7 activation in cells treated with Tan IIA using a cell analyzer. (E) Quantification of caspase-3/7 activation. Data are presented as the mean ± SD, n=5. **P<0.01 compared with the control. Tan IIA, tanshinone IIA.
of Tan IIA for 48 h, the expression levels of Bax, cleaved caspase-3 and cleaved caspase-9 were significantly increased. Bcl-2 expression significantly decreased. Thus, there was a dose-dependent increase in the expression ratio of Bax/Bcl-2. In the Tan IIA-treated SiHa cells, cytochrome c was released from the mitochondria to the cytosol in a dose dependent manner.

**Tan IIA downregulates the Akt/mTOR signaling pathway and inhibits glycolysis.** The expression of GLUT1 was detected by western blotting. The western blot results revealed that Tan IIA decreased the expression of GLUT1, PKM2, and HK2 (Fig. 5), confirming inhibition of glycolysis in SiHa cells treated with Tan IIA. The Akt/mTOR pathway serves a major role in the activation of aerobic glycolysis in tumors. Therefore, it was determined whether the Akt/mTOR signaling pathway was involved in regulation of aerobic glycolysis in the Tan IIA-treated SiHa cells. Treatment with Tan IIA resulted in a dose-dependent decrease of the phosphorylation of Akt and mTOR (Fig. 6). HIF-1α mediates transformation of cell metabolism, whereas the PI3K/AKT pathways are involved in the regulation of HIF-1α. As revealed in Fig. 6, Tan IIA inhibited the expression of HIF-1α in SiHa cells.

**Effect of Tan IIA on tumor growth in vivo.** U14 tumor-bearing Kunming mice were used to determine the antitumor effects of Tan IIA in vivo. When the the tumor size of mice reached 150 mm³, they were randomly divided into 5 groups. Mice were intraperitoneally administered with CTX (25 mg/kg) and Tan IIA (three doses) for 14 days. As revealed in Fig. 7A, the tumor in the control group grew rapidly, whereas the tumors in the mice treated with CTX and Tan IIA grew significantly slower. The body weight of the mice in the Tan IIA-treated group gradually increased but did not significantly differ from the control group, suggesting that Tan IIA did not demonstrate any significant toxic effect. At the end of the experiment, the mice were sacrificed, and the size of the tumors and tumor weights were measured. The results revealed that the tumor weight and volume in the CTX- and Tan IIA-treated groups decreased compared with the control group, in which the high dose of Tan IIA resulted in mice with a tumor weight similar to that in the CTX-treated group. The diameter of the tumor in each group is revealed in Table S1. The maximum tumor volume in each group is revealed in Table SII. The tumor inhibition rate in the CTX-treated group was 65.1%, whereas the rate in mice treated with a high dose (40 mg/kg/day) of Tan IIA was 72.7% (Fig. 7C and D and Table SIII). Pathological analysis of the tumor tissues revealed that tumors in the U14 model group exhibited invasive growth and rapid diffusion with high degrees of tumor cell proliferation. CTX-treated tumor cells exhibited unclear structures with regional necrosis, clear cell edema and a large number of disintegrated granular cells. Following treatment...
with Tan IIA, the tumor cells demonstrated regional necrosis, with shrunken cell volumes, nuclear condensation and clear interstitial edema occasionally infiltrated with inflammatory cells.

Figure 5. Tan IIA induces changes in the expression of GLUT1, PKM2 and HK2 in SiHa cells. (A) Following treatment with Tan IIA for 48 h, the expression of GLUT1, PKM2, and HK2 was assessed by western blot analysis. (B) Densitometric values were normalized by β-actin and expressed as the mean ± SD, n=3. **P<0.01 compared with the control. Tan IIA, tanshinone IIA.

Figure 6. Tan IIA induces changes in the expression of members of the Akt/mTOR signaling pathway and HIF-1α in SiHa cells. (A) Following treatment with Tan IIA for 48 h, the protein expression levels were determined using western blot analysis. (B) Relative expression of p-AKT/AKT. (C) Relative expression of p-mTOR/mTOR. (D) Relative expression of HIF-1α are presented as the mean ± SD, n=3. **P<0.01 compared with the control. Tan IIA, tanshinone IIA.
Discussion

The energy required for proliferation of cancer cells is obtained by glycolysis which is less efficient than aerobic oxidation of glucose (30). The use of glycolysis as the predominant source of energy is associated with certain factors, including upregulation of critical enzymes involved in glycolysis and glucose transporters. Concurrently, expression of enzymes involved in oxidative phosphorylation is downregulated. High glycolytic metabolism has been reported to be associated with resistance to apoptosis in cancer following treatment with anticancer drugs (31,32). Tan IIA has been demonstrated to inhibit cell viability of cervical cancer by decreasing the expression of HPV oncogenes (26). However, the effect of Tan IIA on the inhibition of glycolysis in cervical cancer is still unknown. Therefore, in the present study, the effect of Tan IIA on inducing apoptosis and inhibiting glycolysis in cervical cancer and its possible mechanism were examined.

There are several subtypes of HPV, including high-risk subtypes which are associated with cancer development (33). More than 20 common subtypes of high-risk HPVs exist, with HPV16 being the most prevalent (34). The present study demonstrated that Tan IIA markedly decreased the cell viability of SiHa, HeLa, and C33a cervical cancer cells. Treatment with Tan IIA resulted in a greater decrease in cell viability in SiHa cells compared with HeLa and C33a cells. Therefore, SiHa cells (HPV 16-positive cells) were selected to determine the mechanism underlying the effects of Tan IIA. High-risk HPVs, including HPV16 and HPV18 result in the expression of oncogenes, E6 and E7. E6 and E7 combine to tumor suppressor p53 and Rb, individually. This causes p53 degradation and loss of Rb products (35-37). The results of the present study revealed that following treatment Tan IIA, the mRNA and protein expression levels of E6 and E7 protein were decreased in SiHa cells. Abnormal cell proliferation and differentiation, and apoptotic imbalance are also important
causes of tumorigenesis (38). A number of chemotherapeutic agents affect cancer cells, inducing apoptosis. Apoptotic cells display characteristic morphological changes, such as cell shrinkage, cytoplasmic vacuolation, chromatin condensation, nuclear fragmentation, and cell blebbing, to produce apoptotic bodies (39,40). Hoechst 333258 staining results revealed typical apoptotic morphology in Tan IIA-treated SiHa cells. Fluorescence correlation spectroscopy revealed that the number of apoptotic cells increased as the concentration of Tan IIA was increased. The mechanism through which Tan IIA-induced apoptosis was examined, and the results revealed a marked decrease in Bcl-2 expression in the cells treated with Tan IIA, significantly increased Bax expression levels, and an increased Bax/Bcl-2 ratio (41). Bcl-2 is an anti-apoptotic protein involved in the intrinsic apoptotic pathway which inhibits apoptosis by binding and subsequently inhibiting proapoptotic molecules, such as Bax and Bak (42). Therefore, changes in the Bax/Bcl-2 ratio may explain the increased rate of apoptosis in the Tan IIA-treated SiHa cells.

Apoptotic factors, such as cyto c, serve a crucial role in the mitochondrial apoptotic pathway, activating the activity of caspases in cancer cells. Chemotherapeutic agents and cytotoxic drugs frequently induce the release of cyto c from mitochondria into the cytosol resulting in activation of caspase-9. Subsequently, pro-caspase-3 is transformed into its active form (caspase-3) by caspase-9-mediated cleavage. Poly-ADP ribose polymerase may be cleaved by caspase-3, causing DNA fragmentation and apoptosis (43). The results of the present study revealed that Tan IIA treatment resulted in the release of cyto c from the mitochondria into the cytosol and the activation of caspase-9 in SiHa cells. Subsequently, activated caspase-9 impacted the downstream caspase-3 proenzyme and activated caspase-3, ultimately inducing apoptosis in SiHa cells.

The researcher and scientist Warburg revealed a phenomenon in which tumors prefer to utilize the energy which is supplied by glycolysis instead of aerobic oxidation of glucose even when there is an ample supply of oxygen. Anaerobic respiration in cancer cells leads to a considerable increase in the use of glucose (44,45). The results of the present study revealed that Tan IIA treatment may suppress glucose uptake and extracellular lactic acid generation in SiHa cells. GLUT1, PKM2, and HK2 were all downregulated in the Tan IIA treatment group. GLUT1 is an important glucose transporter, which is a rate-limiting enzyme of glucose transport. Increased expression of GLUT1 is associated with proliferation, migration and invasion (46). HK2 and PKM2 isozyme expression is increased in a number of malignant types of cancer associated with a propensity for invasion and metastasis (47). The Akt/mTOR signaling is associated with hypoxia signaling transduction. At the translational level, the phosphorylation of Akt and mTOR can increase the hypoxia-induced expression of HIF-1α, which regulates intracellular glucose utilization and angiogenesis, and promotes stabilization and activation, eventually promoting tumor cell growth (48-50). The results of present study revealed that Tan IIA treatment decreased the expression of HIF-1α and concurrently decreased the phosphorylation of Akt and mTOR in SiHa cells. This indicates that regulation of HIF-1α by the Akt/mTOR pathway was involved in the inhibition of glycolysis when treated with Tan IIA.

In vitro, Tan IIA demonstrated significant antitumor effects in SiHa cells, and the possible mechanism was associated with inhibition of glycolysis. Therefore, the antitumor effect of Tan IIA in carcinoma-bearing mice was determined. The results of the present study revealed that carcinoma-bearing mice treated with Tan IIA presented with a significant reduction in the tumor volume and weight and there was no notable difference in the toxicity between the different groups of mice. The present study highlights the potential of Tan IIA as a therapeutic alternative.

In conclusion, the present study revealed that treatment with Tan IIA inhibited cell viability of cervical cancer SiHa cells and induced apoptosis. The possible mechanism was associated with the expression of the oncogenes E6 and E7, decreasing glycolysis through inhibition of the intracellular Akt/mTOR pathway and the associated HIF-1α signaling. Tan IIA treatment increased apoptosis in SiHa cells, and this effect may be associated with inhibition of glycolysis.

Acknowledgements

Not applicable.

Funding

The present study was supported by the Project Agreement for Science and Technology Development, Jilin Province (nos.20180101142JC, 20190701062GH, 20130101157JC) and the Science and Technology Project of Jilin Provincial Department of Education (JJKH20190662KJ, JJKH20191062KJ, no. 2011286).

Availability of data and materials

All data generated or analyzed during this study are included in this published article.

Authors' contributions

ZL, WZhu and WZhang performed the experiments and participated in designing some experiments. XK and XC participated in the experiment of cell experiment and western blot analysis. XS and RZ performed the PCR and flow cytometry experiments, and WZhu, WZhang and RZ performed some of the in vivo experiments. WZhu wrote the manuscript. All authors have read and approved the manuscript and agree to be accountable for all aspects of the research in ensuring that the accuracy or integrity of any part of the work are appropriately investigated and resolved.

Ethics approval and consent to participate

All animal experiments were performed in compliance with the guidelines of the Ethics Committee for Animal Use and Care of Beihua University. This committee approved the experiments in the present study.

Patient consent for publication

Not applicable.
Competing interests
The authors declare that they have no competing interests.

References


